Notably, we cannot rule out the possibility that this inhibitory effect may also be attributed to the decreased viability of IM-resistant GIST cells that were previously knocked down for CLDN1 and subsequently treated with IM. The gene discussed is CLDN1; the disease is gastrointestinal stromal tumor.